Phagocytosis checkpoints as new targets for cancer immunotherapy
Cancer immunotherapies targeting adaptive immune checkpoints have substantially
improved patient outcomes across multiple metastatic and treatment-refractory cancer types …
improved patient outcomes across multiple metastatic and treatment-refractory cancer types …
Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS
With a growing aged population, there is an imminent need to develop new therapeutic
strategies to ameliorate disorders of hematopoietic aging, including clonal hematopoiesis …
strategies to ameliorate disorders of hematopoietic aging, including clonal hematopoiesis …
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Background Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many
myeloproliferative neoplasms, but the molecular pathogenesis of myeloproliferative …
myeloproliferative neoplasms, but the molecular pathogenesis of myeloproliferative …
Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study
DA Sallman, MM Al Malki, AS Asch… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a
don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by …
don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by …
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis
Atherosclerosis is the disease process that underlies heart attack and stroke. Advanced
lesions at risk of rupture are characterized by the pathological accumulation of diseased …
lesions at risk of rupture are characterized by the pathological accumulation of diseased …
Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies
SM Ansell, MB Maris, AM Lesokhin, RW Chen… - Clinical Cancer …, 2021 - AACR
Abstract Purpose: TTI-621 (SIRPα-IgG1 Fc) is a novel checkpoint inhibitor that activates
antitumor activity by blocking the CD47 “don't eat me” signal. This first-in-human phase I …
antitumor activity by blocking the CD47 “don't eat me” signal. This first-in-human phase I …
Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies
MP Chao, CH Takimoto, DD Feng, K McKenna… - Frontiers in …, 2020 - frontiersin.org
In recent years, immunotherapies have been clinically investigated in AML and other
myeloid malignancies. While most of these are focused on stimulating the adaptive immune …
myeloid malignancies. While most of these are focused on stimulating the adaptive immune …
[HTML][HTML] The clinical impact of the molecular landscape of acute myeloid leukemia
S Kayser, MJ Levis - Haematologica, 2023 - ncbi.nlm.nih.gov
Research into the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has
led to remarkable advances in our understanding of the disease. Mutations now allow us to …
led to remarkable advances in our understanding of the disease. Mutations now allow us to …
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Small-cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer with limited
treatment options. CD47 is a cell-surface molecule that promotes immune evasion by …
treatment options. CD47 is a cell-surface molecule that promotes immune evasion by …
Stem-cell aging and pathways to precancer evolution
Stem-Cell Aging and Pathways to Precancer Evolution | New England Journal of Medicine Skip
to main content The New England Journal of Medicine homepage Advanced Search SEARCH …
to main content The New England Journal of Medicine homepage Advanced Search SEARCH …